By comparison, the S&P 500 index returned 12.8% last month, as the market made a strong comeback from March's big coronavirus-driven sell-off, which drove the index (including dividends) down 12.4%.
So far in May, through Monday, Immunomedics stock is up just over 8%, while the broader market has returned less than 1%.
We can attribute Immunomedics stock's powerful performance last month largely to the company's April 23 announcement that the Food and Drug Administration (FDA) approved its drug Trodelvy for use in metastatic triple-negative breast cancer (TNBC).
Shares shot up 19.2% that day, while the market was flat, and continued to move higher through the end of the month.
As my colleague Todd Campbell wrote at the time, the "FDA's blessing clears the way for Immunomedics to begin marketing Trodelvy's advantages as a third-line treatment option."
April's news was particularly sweet for investors in Immunomedics, which has had a turbulent year and half. The FDA declined to approve the company's TNBC drug in January 2019 because of issues at the manufacturing plant where it was to be produced.
That said, cautious optimism is the name of the game as the company moves into a commercialization phase.